Key Takeaways
- Cenexi deal closes, reshaping the P&L: Revenue jumped 41% YoY on two months of Cenexi consolidation, but net profit fell 15% as higher depreciation and a forex loss offset the top-line lift.
- US base business stabilizes sequentially: US sales grew 23% QoQ on new launches and volume, with price erosion nearly neutral at ~1% negative. The drag from two lost customers is fading as those products find new homes.
- Cenexi’s 76% gross margin is the prize, but integration costs are the near-term reality: A summer shutdown will compress Q2 revenue, and management sees margin improvement starting in 1–2 quarters, with a longer path to high-teens margins.
- Complex injectables pipeline is loading, but approvals are still quarters away: 19 complex products filed or filing soon, with first approvals expected in late FY24 or early FY25. One complex peptide launched last quarter.
- What to watch next quarter: Whether Enoxaparin shipments resume as guided, the pace of the 12–13 relaunches from the exited customer portfolio, and how much Cenexi’s summer shutdown weighs on consolidated revenue.
The Cenexi Acquisition: What It Adds and What It Costs Now
- Deal mechanics: Gland closed the acquisition of 100% of Cenexi on April 27, 2023, so Q1 FY24 includes only two months of consolidation. Cenexi contributed 37% of the quarter’s reported revenue growth.
- Gross margin uplift: Cenexi’s standalone gross margin is 76%, driven by unique products where few CDMOs compete, including a US-exclusive product and a pre-filled syringe oncology product. This lifted consolidated gross margin to 63% from 56% YoY.
- The profit drag: Net profit fell 15% despite 10% EBITDA growth, because Cenexi brought higher depreciation and the quarter saw a forex loss versus a gain in the prior year. Manpower costs rose 160% YoY and power and fuel costs rose 46%, both entirely from Cenexi.
- Summer shutdown warning: Cenexi sites will take up to four weeks of annual summer shutdown during Q2. Management expects next quarter’s revenue to be in a similar range as the two-month consolidation, implying a sequential step-down in the contribution rate.
- Integration plan: A dedicated cross-functional team has built a function-by-function integration plan. Management is assessing Cenexi’s future capex needs and sees plenty of room to improve operational efficiency, since current OE levels are low relative to Gland’s own sites.
- Synergy levers: Three buckets: technology (oncology pre-filled syringes, colored products, sterile gels, and a new liposomal product contract at Cenexi that Gland does not have in-house), partner-network access to take products to other markets, and cost benefits from moving production to India.
Srinivas Sadu: "The standalone margin of Gland probably is it's a long shot. It will take some time, but at least the margin improvement you should see from I think the target internally is 2 quarters from now, 1 to 2 quarters because the base costs are higher compared to here."
US Business: Rebuilding After Customer Exits
- Sequential recovery, YoY still negative: US sales grew 23% QoQ but declined 8% YoY. The YoY decline reflects the exit of two key customers last year and a substantial drop in Enoxaparin sales from inventory rationalization.
- Growth composition: New launches contributed 10–11% of QoQ growth, volume growth added 4–5%, and pricing was nearly stable at ~1% negative. Higher volumes came from older products including Esmolol, Caspofungin Acetate, Rocuronium, Heparin, and Acetylcysteine.
- Customer normalization progressing: Most products from the two exited customers have found new homes and are in various stages of launch. Sagent acquired the GPO contracts tied to Gland’s products from one of those exits, and has started placing orders as it sells through inherited inventory. Management expects 12–13 more products from this portfolio to launch next quarter.
- Enoxaparin reset: The agreement with Kabi is active, and Kabi is rationalizing inventory. Management expects shipments to resume next quarter, with Kabi’s expectations at roughly 1.5 crore syringes per year. The reduced dependence on Heparin and Enoxaparin, down from 25–27% of US sales last year, is framed as a positive because newer, more profitable products are taking the load.
- Drug shortage tailwind: Many oncology products are in shortage in the US, and Gland is working on opportunities. Reaction time is longer because oncology product procurement cycles are extended, and management cannot predict how long shortages will last.
Srinivas Sadu: "So, kind of price erosion kind of it's neutral. If you look at our growth coming from quarter-on-quarter, the growth came from new launches, about 10%, 11% and volume growth about 4%, 5%. But from prices, it's almost stable. I think 1% negative or something."
Complex Injectables Pipeline: Building the Next Margin Tier
- Filing cadence: Seven complex products already filed, four more to be filed this year (total 11), and another eight in the next 12–14 months (total 19). Cenexi’s liposomal technology will add further products to this pipeline.
- Pipeline composition: Four complex peptides, one emulsion, seven hormonal suspension products, two microspheres, one nanosuspension, and four normal suspension products. One complex peptide launched last quarter; it is not a large product but has limited competition.
- Approval timeline: First set of approvals expected in the last quarter of FY24 or first quarter of FY25, based on goal dates received. That means the revenue contribution from this pipeline is still several quarters away.
- Technology transfer projects: Several completed in recent quarters from big pharma, aimed at entering higher-margin product portfolios. These are distinct from the complex injectables filings and represent a nearer-term margin lever.
Rest-of-World and Other Markets: Pruning for Profitability
- ROW strategy shift: Revenue in ROW markets has been concentrated in low-margin products like Enoxaparin and Heparin. Management is now limiting sales in markets where margins are too low and focusing on high-margin business, arguing that Cenexi’s revenue contribution gives them the room to make this trade-off. Most of the low-margin exit is already done.
- Heparin backward integration: Gland is not exiting Heparin and Enoxaparin entirely. It is approving several crude suppliers for Heparin to reduce costs and improve operational efficiencies, while being more selective in selling.
- China progress: One product launched last quarter, one more close to approval and expected to launch in the subsequent quarter, and four products expected to launch in the next 9–12 months. The portfolio is selected to avoid tender-based products, and pricing is better than the US from a gross margin perspective.
- India business: The portfolio is mostly hospital injectable products under NLEM price control. High GMP compliance costs make it difficult to compete in the tender market. Management is evaluating a branded business entry but not in the near term.
- Biosimilars: One plasma protein contract signed, described as similar to a biosimilar. Broader progress is slow due to tight investment conditions in that sector, though Gland is interacting with many customers.
Srinivas Sadu: "Some of the products where it's very low margin, especially the Enoxa and Heparin. Because it's a low-margin business, it's time to focus on the high margin. Now that the revenue we have high revenue coming from Cenexi business also, I think it's time for us to increase profitability."
Competitive Landscape and Pricing Discipline
- Chinese competition rationalizing: Management observed aggressive pricing from Chinese entrants in the recent past but sees behavior becoming more reasonable. The view is that players are realizing aggressive pricing is unsustainable long-term, especially as FDA inspections intensify and target facilities more aggressively.
- Pfizer disruption limited: The products disrupted at Pfizer’s injectable facility are mostly not in Gland’s portfolio. Two products had already moved to Gland’s facilities earlier this year, and there may be opportunity for one or two more, but management does not see it as substantial.
- Profit share dynamics: Profit share historically moves in the 8–11% range. Combined milestone and profit share income was 11% of standalone sales in Q1 FY24. New customer contracts carry higher profit share contractually because milestone income is available for most products, but pricing can bring the end result to a similar level.
Srinivas Sadu: "There is an aggressive pricing, which happened, I would say, still recent past. We see now a bit reasonable in terms of the launches what we have made in the recently. So I think people are realizing long-term it doesn't work with that kind of an aggressive pricing, especially with the FDA inspections happening and going after aggressively the facilities."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| US sequential growth | Steady QoQ growth, no decrease expected | Ongoing from Q1 FY24 |
| Enoxaparin US recovery | Shipments to resume under active Kabi agreement; Kabi expects ~1.5 crore syringes/year | From Q2 FY24 |
| Relaunches from exited customer portfolio | 12–13 products to launch | Q2 FY24 |
| Cenexi summer shutdown impact | Up to 4 weeks shutdown; Q2 revenue expected in similar range as the 2-month Q1 consolidation | Q2 FY24 |
| Cenexi margin improvement | Improvement visible as base costs are higher; internal target 1–2 quarters out | Q3–Q4 FY24 |
| China product launches | 4 products expected to launch | Next 9–12 months |
| Complex injectable approvals | First set of approvals expected | Q4 FY24 or Q1 FY25 |
| Complex injectable filings | 4 more filings this year (total 11), 8 more in next 12–14 months (total 19) | FY24 and FY25 |
| Cenexi annual revenue | Last year ~EUR 190 million; assume similar range this year | FY24 |
Key Metrics
| Metric | Q1 FY24 |
|---|---|
| Revenue from operations | ₹1,208.7 cr, +41% YoY (37% from Cenexi consolidation, 4% base business growth) |
| Gross margin | 63%, up from 56% in Q1 FY23 |
| EBITDA | ₹298.2 cr, +10% YoY |
| EBITDA margin | 25% consolidated; base business maintained 30% |
| Net profit | ₹194.1 cr, -15% YoY |
| PAT margin | 16% |
| Effective tax rate | 25.7% |
| R&D expense | ₹45.7 cr, 5% of revenue from operations |
| Base business revenue growth | 4% YoY |
| U.S. market revenue growth | 23% QoQ, -8% YoY |
| Rest of World revenue growth | 62% YoY, 18% of Q1 FY24 revenue |
| India market revenue growth | 27% YoY, 7% of Q1 FY24 revenue |
| Profit share and milestone income | 11% of standalone revenue |
| Cash flow from operations | ₹62.9 cr for the first 3 months |
| Cash conversion cycle | 233 days |
| Net cash position | ₹1,635.6 cr as of June 30, 2023 |
| ANDA filings | 337 total filings, 270 approved, 67 pending as of June 30, 2023 |
| U.S. product launches in Q1 | 23 molecules launched |
| Cenexi revenue (2 months) | ₹321.4 cr, gross margin of 76%, EBITDA of ₹34.7 cr |